Accumulating evidence indicates that GSK3β is aberrantly activated in injured renal parenchymal cells, where it exacerbates CKD by promoting fibrogenesis, glomerulosclerosis, and tubulointerstitial damage [25,26,91,113–115]. Here, GSK3B is linked to chronic kidney disease.